Search

everythinglearnresearchcommunity

for

Search:↓

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Suppressing certain hormones might help prevent prostate cancer.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

PSA levels could help detect illegal steroid use in female athletes but face challenges like cost and PCOS prevalence.

PSA levels are higher in women with PCOS, but FAI is a more accurate marker for diagnosis.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.

Finasteride treats hair loss but may affect prostate cancer detection.

Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Higher PSA levels are linked to more hirsutism in women with PCOS.

The document suggests more research is needed to understand the link between baldness and prostate cancer.

Serum triglyceride levels are not linked to prostate cancer risk.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Vertex pattern hair loss linked to higher prostate cancer risk.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Dutasteride may help shrink prostate cancer tumors.

Physical activity, height, and smoking affect prostate cancer risk.

Age, race, family history, and certain genetic factors increase prostate cancer risk.

Flutamide rarely causes liver toxicity in prostate cancer patients.

Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.

The IPP index is linked to storage symptoms and leftover urine, and may help manage urinary tract symptoms.

A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.